The Embolotherapy Market was valued at USD 4,084.29 million in 2024 and is expected to grow at a strong CAGR of around 8.1% during the forecast period (2025-2033F), driven by the rising prevalence of cancer, vascular diseases, and other chronic conditions requiring minimally invasive procedures, coupled with technological advancements in embolic agents and devices that enhance safety and efficacy.
Embolotherapy is an intervention method in medicine that involves purposefully blocking blood vessels to treat a number of conditions, with the majority being cancers, vascular malformations, and uncontrollable bleeding. It is performed by interventional radiologists under imaging guidance and involves the injection of embolic agents (microspheres, coils, plugs, or liquid) into a target site so as to limit blood flow. It may reduce or kill tumors by decreasing blood flow to the tumor, preventing bleeding, or slowing blood flow prior to surgery. Embolotherapy has the advantage of a shorter recovery period, less surgical risk, and preservation of organs, which makes embolotherapy a choice over the conventional open surgical procedures.
The Embolotherapy market is set to show a growth rate of about 8.1% during the forecast period (2025-2033F). The embolotherapy market is increasing because the target diseases, like liver cancer, uterine fibroids, and arteriovenous malformations, are increasingly being treated using minimally invasive procedures. The evolution of embolic agents is on the rise, with the introduction of drug-eluting beads and bioresorbable materials, as well as liquid embolic agents, improving treatment precision, safety, and outcomes, thereby increasing adoption rates. Increase in demand is further motivated by the desire of patients to favor those procedures that have shorter recovery periods and lower complication rates. Moreover, the growth of interventional radiology centers, favorable reimbursement policies in developed countries, and increasing investments in healthcare in emerging markets are driving the market.
Access sample report (including graphs, charts, and figures) - https://univdatos.com/reports/embolotherapy-market?popup=report-enquiry
List of Top Companies Operating in Embolotherapy Worldwide:
The global embolotherapy market has several major players, including Boston Scientific Corporation, Merit Medical, Medtronic Inc., Terumo Medical Corporation, and Stryker. More information about these companies has been provided below:
1. Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, medical-surgical and cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents, electrocautery-enhanced delivery systems, and direct visualization systems. The company also has endoluminal surgery and infection prevention portfolios, which include devices to treat urological conditions, including ureteral stents, catheters, guidewires, urinary and bowel dysfunction, sheaths, balloons, and single-use digital flexible ureteroscopes, to treat neurological movement disorders and manage chronic pain.
Related Reports –
Cerebral Embolic Protection Devices Market
Therapeutic Plasma Exchange Market
2. Merit Medical
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, cardiovascular and endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products, peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products. It also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs, coating services for medical tubes and wires, and sensor components for microelectromechanical systems. It sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers.
3. Medtronic Inc.
Medtronic, Inc. manufactures and sells device-based medical therapies. Its products include pacemakers, insertable cardiac monitors, implantable defibrillators, leads and delivery systems, ablation products, electrophysiology catheters, coronary and peripheral stents and related delivery systems, therapies for uncontrolled hypertension, endovascular stent graft systems, heart valve replacement technologies, and cardiac tissue ablation systems. Additionally, it manufactures and sells image-guided surgery and intraoperative imaging systems. Medtronic, Inc. was founded in 2015 and is headquartered in Minneapolis, Minnesota. Medtronic, Inc. operates as a subsidiary of Medtronic plc.
4. Terumo Medical Corporation
Terumo Medical Corporation manufactures medical devices and supplies. It offers interventional systems, medical products, and pharmaceutical solutions, including embolotherapy devices. The company also provides services to cardiac Cath labs. It serves customers worldwide. Terumo Medical Corporation was formerly known as Kimble-Terumo, Inc. and changed its name to Terumo Medical Corporation in August 1980. The company was founded in 1972 and is headquartered in Somerset, New Jersey, with locations in the United States and internationally. Terumo Medical Corporation operates as a subsidiary of Terumo Corporation.
5. Stryker
Stryker Corporation operates as a medical technology company. It operates through two segments, medical-surgical and neurotechnology, and orthopaedics. The medical-surgical and neurotechnology segment offers surgical equipment, surgical navigation systems, endoscopic and communication systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, and artificial intelligence-assisted virtual care platform technology, as well as minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke, including embolotherapy solutions. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries.
Contact Us:
Email - contact@univdatos.com
Website - www.univdatos.com
